Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CYDY |
---|---|---|
09:32 ET | 82989 | 0.15 |
09:41 ET | 402 | 0.1539 |
09:59 ET | 3247 | 0.15245 |
10:01 ET | 5000 | 0.15245 |
10:12 ET | 20000 | 0.153871 |
10:17 ET | 6000 | 0.15245 |
10:32 ET | 20000 | 0.15216 |
10:33 ET | 104428 | 0.145 |
10:39 ET | 4525 | 0.1475 |
10:42 ET | 300 | 0.1475 |
10:48 ET | 500 | 0.148875 |
10:55 ET | 250 | 0.15 |
11:04 ET | 200 | 0.14945 |
11:08 ET | 9000 | 0.1489 |
11:09 ET | 2055 | 0.148 |
11:13 ET | 6310 | 0.14775 |
11:29 ET | 23024 | 0.1475 |
11:33 ET | 1976 | 0.1475 |
11:40 ET | 1000 | 0.14716 |
12:18 ET | 30000 | 0.145 |
12:27 ET | 25000 | 0.14745 |
12:30 ET | 6500 | 0.1475 |
12:38 ET | 95375 | 0.145 |
12:39 ET | 25800 | 0.1487 |
01:06 ET | 3000 | 0.1468 |
01:24 ET | 35000 | 0.145 |
01:32 ET | 100 | 0.145 |
01:37 ET | 4366 | 0.1472 |
01:44 ET | 10697 | 0.148 |
01:50 ET | 300 | 0.148 |
02:06 ET | 10380 | 0.1479 |
02:27 ET | 1000 | 0.14745 |
02:33 ET | 30000 | 0.147 |
02:38 ET | 7177 | 0.147 |
02:51 ET | 30260 | 0.148692 |
02:54 ET | 1000 | 0.149 |
02:56 ET | 1800 | 0.14845 |
03:12 ET | 2500 | 0.14856 |
03:14 ET | 7500 | 0.1479 |
03:32 ET | 4829 | 0.1488 |
03:36 ET | 5536 | 0.1488 |
03:38 ET | 5000 | 0.1488 |
03:45 ET | 7000 | 0.14875 |
03:54 ET | 4650 | 0.14875 |
03:56 ET | 2500 | 0.1485 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cytodyn Inc | 149.0M | -2.7x | --- |
Regulus Therapeutics Inc | 148.0M | -1.4x | --- |
Zura Bio Ltd | 151.7M | -0.8x | --- |
Achieve Life Sciences Inc | 154.1M | -3.0x | --- |
Aeon Biopharma Inc | 162.5M | -4.1x | --- |
Gossamer Bio Inc | 166.4M | -0.5x | --- |
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. The Company is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. Its core areas of clinical development are human immunodeficiency viruses (HIV), non-alcoholic steatohepatitis (NASH), and solid tumors in oncology. The areas of clinical focus in HIV are the lifting of the clinical hold, creation of a long-acting formulation of leronlimab and an HIV functional cure in using adenovirus vectors (AAV). In NASH, its focus is on the general population of those affected by NASH, and the subpopulation of patients with NASH and HIV. Regarding oncology, its focus remains on combination therapy for solid tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $149.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 993.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.23 |
EPS | $-0.06 |
Book Value | $-0.12 |
P/E Ratio | -2.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.